|
|
|
|
Small patient populations, complex study designs, recruitment barriers, and regulatory considerations can create significant challenges for rare disease sponsors. Explore seven of the biggest obstacles in rare disease clinical trials—and practical strategies for overcoming them.
|
|
|
|
|
Limited patient populations, fragmented care pathways, and specialized treatment centers make traditional site selection approaches challenging in rare disease. Learn how patient insights, real-world data, advocacy network can help identify sites with genuine patient access and build more realistic enrollment strategies.
|
|
|
|
|
For rare disease sponsors, meaningful relationships with patient advocacy organizations can improve more than awareness. See how structured PAO engagement can inform protocol design, reduce participation barriers, and strengthen recruitment and retention.
|
|
|
|
|
Recruiting patients with an acute, low-prevalence disease requires speed, close site collaboration, and a highly focused strategy. See how Ergomed used rapid site activation and intensive investigator engagement to accelerate enrollment in a global Phase III Anti-GBM disease study.
|
|
|
|
|
Developing therapies for ultra-rare pediatric cancers brings scientific, regulatory, and ethical complexity. Discover how a tailored development strategy and regulatory expertise helped a biotech sponsor advance a novel therapy toward a Phase I clinical trial.
|
|
|
|
|
|
|
Rare disease trials require a CRO built for complexity. See how Ergomed combines scientific and regulatory expertise with Patient First™ and Site Advantage™ approaches to reduce site burden, strengthen recruitment and retention, and support rare disease programs from early through late-stage development.
|
|
|
|
|
|
|
